These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11897584)

  • 1. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.
    Cynamon MH; Sklaney M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2442-4. PubMed ID: 12878502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
    Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A whole blood bactericidal assay for tuberculosis.
    Wallis RS; Palaci M; Vinhas S; Hise AG; Ribeiro FC; Landen K; Cheon SH; Song HY; Phillips M; Dietze R; Ellner JJ
    J Infect Dis; 2001 Apr; 183(8):1300-3. PubMed ID: 11262217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; Climent A; Royo G
    Int J Antimicrob Agents; 2001 Mar; 17(3):229-31. PubMed ID: 11282270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
    Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
    Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
    J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
    Cynamon M; Sklaney MR; Shoen C
    J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
    Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
    Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
    Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.